DongKook Pharmaceutical Co., Ltd. announced that it expects to receive KRW 10.0000516 billion in funding
July 02, 2018
Share
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:A086450) announced a private placement of 154,084 registered redeemable convertible preferred shares at KRW 64,900 per share for gross proceeds of KRW 10,000,051,600 on July 3, 2018. Each preferred share will have a par value of KRW 2,500. The transaction will include participation from DTR Healthcare PEF. The preferred shares will be convertible into 154,084 registered common shares at fixed conversion price of KRW 1 per share from July 26, 2018 to July 25, 2028. The redemption period of preferred stock will be from July 26, 2023 to July 25, 2028. The payment date is July 18, 2018. The securities to be issued are subject to a lock in period of one year. The transaction has been approved by the board of directors of the company.
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.
DONGKOOK PHARMACEUTICAL CO., LTD. 
